Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Ovarian Neoplasms 2Osteosarcoma 2Neuroblastoma 2Lymphoma, Mantle-Cell 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neutropenia 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Multiple Myeloma 1Microphthalmia, Isolated, with Coloboma 5 1Melanoma 1Medulloblastoma 1Lymphoma, T-Cell, Peripheral 1

Interventions

Cyclophosphamide 32Filgrastim 18Irinotecan 15Topotecan 14Temozolomide 13Vincristine 12Peripheral Blood Stem Cell Transplantation 12Granulocyte Colony-Stimulating Factor 12Etoposide 12Melphalan 11fludarabine 10Carboplatin 9dinutuximab 8Isotretinoin 8Interleukin-2 8Busulfan 8humanized 3F8 anti-GD2 monoclonal antibody 7aldesleukin 7Doxorubicin 73-Iodobenzylguanidine 7sargramostim 6fludarabine phosphate 6Vorinostat 6Zoledronic Acid 5Stem Cell Transplantation 5Cisplatin 5etoposide phosphate 4Ipilimumab 4Drug Therapy 4ribociclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neuroblastoma × pegfilgrastim × Clear all
NCT03107988 2025-09-15

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
65 enrolled 38 charts
CNS

Neuroblastoma

NCT00075634 2013-09-30

Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma

National Cancer Institute (NCI)

Phase 1 Completed
21 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡